Positron emission tomography in gynecologic cancer

Seminars in Nuclear Medicine

Volumn 36, Issue 1, 2006, Pages 93-104

  Yen, Tzu Chen ^a   Lai, Chyong Huey ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; SQUAMOUS CELL CARCINOMA ANTIGEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENDOMETRIUM CANCER; FEASIBILITY STUDY; GYNECOLOGIC CANCER; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; SALVAGE THERAPY; TROPHOBLASTIC TUMOR; UTERINE CERVIX CANCER;

EID: 28844451985     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.08.004     Document Type: Review

References (136)

1. R. Bos, J.J. van Der Hoeven, E. van Der Wall Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20 2002 379 387
2. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma J Nucl Med 44 2003 224 239
3. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer J Nucl Med 43 2002 39 45
4. T. Torizuka, F. Nakamura, T. Kanno Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma Eur J Nucl Med 31 2004 22 28
5. M. Kunkel, T.E. Reichert, P. Benz Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma Cancer 97 2003 1015 1024
6. V.H. Gerbaudo, S. Britz-Cunningham, D.J. Sugarbaker Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma Thorax 58 2003 1077 1082
7. H. Lerman, U. Metser, D. Grisaru Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients assessment by PET/CT J Nucl Med 45 2004 266 271
8. T.C. Yen, K.K. Ng, S.Y. Ma Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer J Clin Oncol 21 2003 3651 3658
9. 18F]-2-fluoro-2-deoxy- glucose positron emission tomography for detection of para-aortic lymph node metastases in cervical cancer patients J Nucl Med 44 2003 1775 1783
10. Chao A, Chang YC, Hsueh S, et al: F-18 fluorodeoxyglucose positron emission tomography in the management of endometrial cancer. Eur J Nucl Med Mol Imaging (in press)
11. N.F. Hacker Cervical cancer J.S. Berek N.F. Hacker Practical Gynecologic Oncology (ed 3) 2000 Lippincott Williams & Wilkins Pliladelphia 345 405
12. S.E. Waggoner Cervical cancer Lancet 361 2003 2217 2225
13. F. Landoni, A. Maneo, A. Colombo Randomized study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer Lancet 350 1997 535 540
14. C.H. Lai, J.H. Hong, S. Hsueh Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases Cancer 85 1999 1537 1546
15. P.G. Rose, B.N. Bundy, E.B. Watkins Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer N Engl J Med 15 1999 1144 1151
16. H.M. Keys, B.N. Bundy, F.B. Stehman Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ib cervical carcinoma N Engl J Med 15 1999 1154 1161
17. P.J. Eifel, K. Winter, M. Morris Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer An update of Radiation Therapy Oncology Group (RTOG) study 90-01 J Clin Oncol 22 2004 872 880
18. International Federation of Gynecology and Obstetrics, FIGO staging of gynecologic cancers cervical and vulva Int J Gynecol Cancer 5 1995 319 324
19. P.B. Heller, J.H. Malfetano, B.N. Bunndy Clinical-pathologic study of stage II, III, and IVA carcinoma of the cervix Extended diagnostic evaluation for para-aortic node metastasis -a Gynecologic Oncology Group study Gynecol Oncol 38 1990 425 430
20. F.B. Stehman, B.N. Bundy, P.J. DiSaia Carcinoma of the cervix treated with radiation therapy I A multivariate analysis of prognostic variables in the Gynecologic Oncology Group Cancer 67 1991 2776 2785
21. T.W. Burke, W.J. Hoskins, P.B. Heller Clinical patterns of tumor recurrence after radical hysterectomy in stage IB cervical carcinoma Obstet Gynecol 69 1987 382 385
22. C.J. Wang, C.H. Lai, H.J. Huang Recurrent cervical carcinoma after primary radical surgery Am J Obstet Gynecol 181 1999 518 524
23. H. Sakurai, N. Mitsuhashi, M. Takahashi Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone Patterns of recurrence, latent periods, and prognosis Int J Radiat Oncol Biol Phys 50 2001 1136 1144
24. Y. Eralp, P. Saip, B. Sakar Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix Int J Gynecol Cancer 13 2002 497 504
25. G.M. Sommers, P.W. Grigsby, C.A. Perez Outcome of recurrent cervical carcinoma following definitive irradiation Gynecol Oncol 35 1989 150 155
26. J.H. Hong, C.S. Tsai, C.H. Lai Recurrent squamous cell carcinoma of cervix following definitive radiotherapy Int J Radiat Oncol Biol Phys 60 2004 249 257
27. T.M. Anderson, J.J. McMahon, C.E. Nwogu Pulmonary resection in metastatic uterine and cervical malignancies Gynecol Oncol 83 2001 472 476
28. H.H. Chou, C.C. Wang, C.H. Lai Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma Int J Radiat Oncol Biol Phys 51 2001 442 448
29. H.M. Shingleton, S.J. Soong, M.S. Gelder Clinical and histological factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix Obstet Gynecol 73 1989 1027 1034
30. B. Miller, M. Morris, F. Rutledge Aborted exenteratice procedures in recurrent cervical cancer Gynecol Oncol 50 1993 94 99
31. S. Rutledge, M.S. Carey, H. Prichard Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation Is exenteration always necessary? Gynecol Oncol 52 1994 353 359
32. M. Hockel Laterally extended endopelvic resection Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic sidewall Gynecol Oncol 91 2003 369 377
33. N.A. Mayr, V.A. Magnotta, J.C. Ethrhardt Usefulness of tumor volumetry by magnetic resonance imaging in assessing response to radiation therapy in carcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 35 1996 915 924
34. K. Hatano, Y. Sekiya, H. Araki Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging Int J Radiat Oncol Biol Phys 45 1999 639 644
35. P.G. Rose, L.P. Adler, M. Rodriguez Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging A surgicopathologic study J Clin Oncol 17 1999 41 45
36. P.W. Grigsby, B.A. Siegel, F. Dehdashti Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 19 2001 3745 3749
37. C.S. Tasi, T.C. Chang, C.H. Lai A preliminary report of using FDG-PET to detect extrapelvic lesions in cervical cancer patients with enlarged pelvic lymph nodes shown on MRI/CT images Int J Radiat Oncol Biol Phys 58 2004 1506 1512
38. W.C. Lin, Y.C. Hung, L.S. Yeh Usefulless of (18)F-Fluorodeoxyglucose positon emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings Gynecol Oncol 89 2003 73 76
39. M.J. Reinhardt, C. Ehritt-Braun, D. Vogelgesang Metastatic lymph nodes in patients with cervical cancer Detection with MR imaging and FDG PET Radiology 218 2001 776 782
40. Y. Sugawara, A. Eishruch, S. Kosuda Evaluation of FDG PET in patients with cervical cancer J Nucl Med 40 1999 1125 1131
41. A.D. Williams, C. Cousins, W.P. Soutter Detection of pelvic lymph node metastases in gynecologic malignancy A comparison of CT, MR imaging, and positron emission tomography AJR Am J Roentgenol 177 2001 343 348
42. K. Narayan, R.J. Hicks, T. Jobling A comparison of MRI and PET scanning in surgically staged locoregionally advanced cervical cancer Potential impact on treatment Int J Gynecol Cancer 11 2001 263 271
43. M.D. Esajas, J.M. Duk, H.W. de Bruijn Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer J Clin Oncol 19 2001 3960 3966
44. T. Ohno, Y. Nakayama, S. Nakamoto Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix Cancer 97 2003 3114 3120
45. J.A. Bolli, D.L. Doering, J.R. Bosscher Squamous cell carcinoma antigen Clinical utility in squamous cell carcinoma of the uterine cervix Gynecol Oncol 55 1994 169 173
46. T. Tabata, N. Takeshim, N. Tanaka Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma Tumor Biol 21 2000 375 380
47. L.J. Havrilesky, T.Z. Wong, A.A. Secord The role of PET scanning in the detecting of recurrent cervical cancer Gynecol Oncol 90 2003 186 190
48. S.S. Sun, T.C. Chen, R.F. Yen Value of whole body 18F-fluoro-2- deoxyglusose positron emission tomography in the evaluation of recurrent cervical cancer Anticancer Res 21 2001 2957 2962
49. J.B. Unger, J.J. Ivy, P. Connor Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women Gynecol Oncol 94 2004 212 216
50. S.Y. Ryu, M.H. Kim, S.C. Choi Detection of early recurrence with 18F-FDG PET in patients with cervical cancer J Nucl Med 44 2003 347 352
51. Y. Nakamoto, A. Eisbruch, E.D. Achtyes Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy Gynecol Oncol 84 2002 289 295
52. P.W. Grigsby, B.A. Siegel, F. Dehdashti Posttherapy surveillance monitoring of cervical cancer by FDG-PET Int J Radiat Oncol Biol Phys 55 2003 907 913
53. P.W. Grigsby, A.K. Singh, B.A. Siegel Lymph node control in cervical cancer Int J Radiat Oncol Biol Phys 59 2004 706 712
54. T.C. Chang, K.S. Law, J.H. Hong Positron emission tomography for unexplained serum SCC-Ag elevation in cervical cancer patients - a phase II study Cancer 101 2004 164 171
55. C.H. Lai, K.G. Huang, L.C. See Restaging of recurrent cervical cancer with dual-phase positron emission tomography Cancer 100 2004 544 552
56. T.C. Yen, L.C. See, S.Y. Ma Defining priority of utilizing 18F-fluoro-D-deoxyglucose positron emission tomography for recurrent cervical cancer J Nucl Med 45 2004 1632 1639
57. Y. Yoshida, T. Kurokawa, K. Kawahara Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]- Fluorodeoxyglucose positron emission tomography Preliminary results in three patients Gynecol Oncol 95 2004 597 602
58. F. Dehdashti, P.W. Grigsby, M.A. Mintun Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM Relationship to therapeutic response-a preliminary report Int J Radiat Oncol Biol Phys 55 2003 1233 1238
59. P.J. Ell, G.K. von Sxhulthess PET/CT A new road map Eur J Nucl Med Mol Imaging 29 2002 719 720
60. D. Grisaru, B. Almong, C. Levine The diagnostic accruracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies Gynecol Oncol 94 2004 680 684
61. P. Boyle, M.E. Leon, P. Maisonneuve Cancer control in women. Update 2003 Int J Gynecol Obstet 83 suppl 2003 179 202
62. S.A. Cannistra Cancer of the ovary N Engl J Med 329 1993 1550 1559
63. W.J. Mann, B. Patsner, H. Cohen Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma J Natl Cancer Inst 80 1988 208 209
64. S.C. Dowdy, C.L. Constantinou, L.C. Hartmann Long-term follow-up of women with ovarian cancer after positive second-look laparotomy Gynecol Oncol 91 2003 563 568
65. H.J. Kim, J.K. Kim, K.S. Cho CT features of serous surface papillary carcinoma of the ovary AJR Am J Roentgenol 183 2004 1721 1724
66. A. Qayyum, F.V. Coakley, A.C. Westphalen Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer Gynecol Oncol 96 2005 301 306
67. K.F. Hubner, T.W. McDonald, J.G. Niethammer Assessment of primary and metastatic ovarian cancer by Positron Emission Tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG) Gynecol Oncol 51 1993 197 204
68. D. Grab, F. Flock, I. Stohr Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positive emission tomography Gynecol Oncol 77 2000 454 459
69. A. Rieber, K. Nussle, Stohr Preoperative diagnosis of ovarian tumors with magnetic resonance imaging Comparison with transvaginal sonography, positive emission tomography and histologic findings AJR Am J Roentgenol 177 2001 123 129
70. S. Fenchel, D. Grab, K. Nuessle Asymptomatic adnexal masses Correlation of FDG PET and histopathologic findings Radiology 223 2002 780 788
71. K. Kawahara, Y. Yoshida, T. Kurokawa Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography J Comput Assist Tomogr 28 2004 505 516
72. H. Lerman, U. Metser, D. Grisaru Normal and abnormal 18F-FDG endometrial and ovarian uptake pre- and postmenopausal patients assessment by PET/CT J Nucl Med 45 2004 266 271
73. S. Sironi, C. Messa, G. Mangili Integrated FDG PET/CT in patients with persistent ovarian cancer correlation with histologic findings Radiology 233 2004 433 440
74. Y. Yoshida, T. Kurokawa, K. Kawahara Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer AJR Am J Roentgenol 182 2004 227 233
75. R.A. Kubik-Huch, W. Dorffler, G.K. von Schulthess Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma Eur Radiol 10 2000 761 767
76. O. Drieskens, S. Stroobants, M. Gysen Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer Gynecol Obstet Invest 55 2003 130 134
77. R.S. Brown, S.J. Risher, R.L. Wahl Autoradiographic evaluation of the intratumoral distribution of 2-deoxy-D-glucose and monoclonal antibodies in xenografts of human ovarian adenocarcinoma J Nucl Med 34 1993 75 82
78. H. Minn, L. Kangas, V. Knutilla Determination of 2-fluoro-2-deoxy-D- glucose uptake and ATP level for evaluating drug effects in neoplastic cells Res Exp Med 191 1991 27 35
79. I. Vergote, I. de Wever, W. Tjalma Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian cancer A retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436
80. R.P. Baum, C. Przetak Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET) Q J Nucl Med 45 2001 257 268
81. J.M. Niloff, R.C. Bast, E.M. Schaetzl Predictive value of CA-125 antigen levels in second-look procedures for ovarian cancer Am J Obstet Gynecol 151 1985 981 986
82. S.C. Rubin, W.J. Hoskins, T.B. Hakes Serum CA 125 levels and the surgical findings in patients undergoing secondary operations for epithelial ovarian cancer Am J Obstet Gynecol 160 1989 667 671
83. B. Patsner, T.G. Day Predictive value of CA-125 levels in advanced ovarian cancer Am J Obstet Gynecol 156 1987 440 441
84. P.T. Lavin, R.C. Knapp, G. Malkasian CA 125 for the monitoring of ovarian carcinoma during primary therapy Obstet Gynecol 69 1987 223 227
85. P.G. Rose, K. Reuter, J. Sirois The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second look laparotomy in ovarian cancer Int J Gynecol Cancer 6 1996 213 218
86. S. Kim, J.K. Chung, S.B. Kang [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma Eur J Nucl Med Mol Imaging 31 2004 196 201
87. J.M. Niloff, R.C. Knapp, P.T. Lavin The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer Am J Obstet Gynecol 155 1986 56 60
88. L.W. Fleming Playing the waiting game...the asymptomatic patients with recurent ovarian cancer detected only by rising Ca-125 level Scot Med J 46 2001 81 83
89. M. Markman, K. Webster, K. Zanotti Use of tamoxifen in asymptomatic patients with recurrent small volume ovarian cancer Gynecol Oncol 93 2004 390 393
90. S. Makhija, N. Howden, R. Edwards Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma a retrospective review Gynecol Oncol 85 2002 53 58
91. W.C. Chang, Y.C. Hung, C.H. Kao Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker Neoplasma 49 2002 329 333
92. M. Zimny, W. Siggelkow, W. Schroder 2-[Fluorine-18]-fluoro-2-deoxy-d- glucose positron emission tomography in the diagnosis of recurrent ovarian cancer Gynecol Oncol 83 2001 310 315
93. R.F. Yen, S.S. Sun, Y.Y. Shen Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer Anticancer Res 21 2001 3691 3694
94. M.J. Garcia Velloso, J.F. Boan Garcia, L.M. Villar Luque F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence Comparison with CT scan and CA 125 Rev Esp Med Nucl 22 2003 217 223
95. J.L. Wilder, E. Pavlik, J.M. Straughn Clinical implications of rising CA-125 within the normal range in patients with epithelial ovarian cancer A preliminary investigation Gynecol Oncol 89 2003 233 235
96. T. Kurokawa, Y. Yoshida, K. Kawahara Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range Ann Nucl Med 6 2002 491 493
97. S.M. Cho, H.K. Ha, J.Y. Byun Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer AJR Am J Roentgenol 179 2002 391 395
98. R.E. Bristow, M.G. del Carmen, H.K. Pannu Clinically occult recurrent ovarian cancer patient selection for secondary cytoreductive surgery using combined PET/CT Gynecol Oncol 90 2003 519 528
99. M.J. Reinhardt, A. Matthies, H.J. Biersack PET-imaging in tumors of the reproductive tract Q J Nucl Med 46 2002 105 112
100. J.N. Talbot, D. Grahek, K. Kerrou (18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers Gynecol Obstet Fertil 29 2001 775 798
101. C.P. Morrow, B.N. Bundy, R.J. Kurman Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium A Gynecologic Oncology Group study Gynecol Oncol 40 1991 55 65
102. J.G. Aalders, V. Abeler, P. Kolstad Recurrent adenocarcinoma of the endometrium A clinical and histopathological study of 379 patients Gynecol Oncol 17 1984 85 103
103. M.S. Kao Management of recurrent endometrial cancer Chang Gung Med J 27 2004 639 645
104. A.R. Jeyarajah, C.J. Gallagher, P.R. Blake Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer Gynecol Oncol 63 1996 47 52
105. T.D. Moore, P.H. Phillips, S.R. Nerenstone Systemic treatment of advanced and recurrent endometrial carcinoma current status and future directions J Clin Oncol 9 1991 1071 1088
106. R. Manfredi, P. Mirk, G. Maresca Local-regional staging of endometrial carcinoma role of MR imaging in surgical planning Radiology 231 2004 372 378
107. K.A. Frei, K. Kinkel, H.M. Bonel Prediction of deep myometrial invasion in patients with endometrial cancer clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis Radiology 216 2000 444 449
108. J.M. Duk, J.G. Aalders, G.J. Fleuren CA 125 a useful marker in endometrial carcinoma Am J Obstet Gynecol 155 1986 1097 1102
109. B. Patsner, W.J. Mann The value of preoperative serum CA 125 levels in patients with a pelvic mass Am J Obstet Gynecol 159 1988 873 876
110. D.J. Dotters Preoperative CA 125 in endometrial cancer Is it useful? Am J Obstet Gynecol 182 2000 1328 1334
111. T. Belhocine, C. de Barsy, R. Hustinx Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma Eur J Nucl Med Mol Imaging 29 2002 1132 1139
112. T. Saga, T. Higashi, T. Ishimori Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer Ann Nucl Med 17 2003 197 203
113. T. Nakahara, H. Fujii, M. Ide F-18 FDG uptake in endometrial cancer Clin Nucl Med 26 2001 82 83
114. S.S. Lentz Endometrial carcinoma diagnosed by positron emission tomography a case report Gynecol Oncol 86 2002 223 224
115. N.S. Horowitz, F. Dehdashti, T.J. Herzog Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer GynecolOncol 101 2004 164 171
116. K.C. Podratz, R.E. Symmonds, W.F. Taylor Carcinoma of the vulva Analysis of treatment failures Am J Obstet Gynecol 143 1982 340 347
117. J.M. Heaps, Y.S. Fu, F.J. Montz Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva Gynecol Oncol 38 1990 309 314
118. A. Sedlis, H. Homesley, B.N. Bundy Positive groin lymph nodes in superficial squamous cell vulvar cancer Am J Obstet Gynecol 156 1987 1159 1164
119. M.P. Hopkins, G.C. Reid, G.W. Morley The surgical management of recurrent squamous cell carcinoma of the vulva Obstet Gynecol 75 1990 1001 1005
120. B. Piura, A. Masotina, J. Murdoch Recurrent squamous cell carcinoma of the vulva A study of 73 cases Gynecol Oncol 48 1993 189 195
121. G. Chakalova, A. Karagiozov The surgical management of recurrent carcinoma of the vulva Eur J Gynecol Oncol 14 1993 318 322
122. G. Hruby, C. MacLeod, I. Firth Radiation treatment in recurrent squamous cell cancer of the vulva Int J Radiat Oncol Biol Phys 46 2000 1193 1197
123. K. Tewari, F. Cappuccini, A.M. Syed Interstitial brachytherapy in the treatment of advanced and recurrent vulvar cancer Am J Obstet Gynecol 181 1999 91 98
124. D.E. Cohn, F. Dehdashti, R.K. Gibb Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer Gynecol Oncol 85 2002 179 184
125. M. Bower, E.S. Newlands, L. Holden EMA/CO for high-risk gestational trophoblastic tumours results from a cohort of 272 patients J Clin Oncol 15 1997 2636 2643
126. E. Lehman, D.M. Gershenson, T.W. Burke Salvage surgery for chemorefractory gestational trophoblastic disease J Clin Oncol 12 1994 2737 2742
127. E.S. Newlands, M. Bower, L. Holden Management of resistant gestational trophoblastic tumours J Reprod Med 43 1998 111 118
128. C.M. Feltmate, D.R. Genest, L. Wise Placental site trophoblastic tumour A 17-year experience at the New England Trophoblastic Disease Center Gynecol Oncol 82 2001 415 419
129. World Health Organization Gestational trophoblastic diseases WHO Technical Report Series 1983 WHO Switzerland 692
130. K.D. Bagshawe Choriocarcinoma. A model for tumour markers Acta Oncol 31 1992 99 106
131. H. Hebart, C. Erley, B. Kaskas Positron emission tomography helps to diagnose tumour emboli and residual disease in choriocarcinoma Ann Oncol 7 1996 416 418
132. J. Truenbach, P.L. Pereira, P.E. Huppert Primary choriocarcinoma of the pulmonary artery mimicking pulmonary embolism Br J Radiol 70 1997 843 845
133. H. Zhuang, A.J. Yamamoto, N. Ghesani Detection of choriocarcinoma in the lung by FDG positron emission tomography Clin Nucl Med 26 2001 723
134. J. Dose, K. Bohuslavizki, B. Huneke Detection of intramural choriocarcinoma of the uterus with 18F-FDG-PET. A case report Clin Positron Imaging 3 2000 37 40
135. S. Sironi, M. Picchio, G. Mangili [18F]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumour Preliminary results in three patients Gynecol Oncol 91 2003 226 230
136. Chang TC, Yen TC, Ma SY, et al: 18F-fluoro-D-deoxyglucose positron emission tomography of trophoblastic tumor: A pilot study. Eur J Nucl Med Mol Imaging (in press)